Company profile: United Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology products and patient support services, including an Expanded Access Program for investigational drugs; ASSIST Access Solutions for medicine access and financial assistance; Archways educational resources for patients on inhaled or oral treprostinil via phone or video; and MyOldMeds.com for secure storage and disposal of unwanted or expired medications.
Products and services
- ASSIST Access Solutions and Support Team: A multichannel service that answers patient/customer questions on accessing United Therapeutics medicines, coordinates financial assistance eligibility, and manages product distribution logistics
- Expanded Access Program: A compassionate-use pathway enabling patients with serious or life-threatening conditions to obtain investigational drugs when no other treatment options are available
- Archways Educational Resource and Support Program: A telehealth-enabled resource for patients prescribed inhaled or oral treprostinil, delivering information and live support via phone or video chat
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to United Therapeutics
SynDevRx
HQ: United States
Website
- Description: Provider of polymer-based drug conjugates for oncology, including evexomostat (SDX-7320), a polymer-drug conjugate that releases a fumagillol derivative in vivo to target cancer and systemic metabolic hormone dysfunction. Sponsors clinical trials across various cancer types, provides an expanded access program, and advances a pipeline focused on cancers sensitive to metabolic hormones, leveraging metabo-oncology and polymer-drug conjugation to improve safety and activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynDevRx company profile →
DiaMedica Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on treatments for stroke, developing DM199, a recombinant human tissue kallikrein-1 (KLK1) intended to treat acute ischemic stroke and cardio-renal diseases by restoring KLK1 levels, and conducting the ReMEDy2 adaptive, randomized, double-blind, placebo-controlled trial to study DM199’s efficacy and safety in acute ischemic stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaMedica Therapeutics company profile →
CB Fleet
HQ: United States
Website
- Description: Provider of feminine care products for personal hygiene and comfort and over-the-counter (OTC) healthcare products addressing common health concerns, serving as a manufacturer, marketer, and distributor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CB Fleet company profile →
Valera Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical services concentrating on development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valera Pharmaceuticals company profile →
Rosemont Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of oral liquid medicines for patients with swallowing difficulties, manufacturing and supplying 130+ formulations across therapeutic categories. Offers R&D for new low-excipient liquid medications, GMP and ICH Q10-compliant, regularly inspected manufacturing, international distribution to 27+ markets, and educational resources for healthcare professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rosemont Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for United Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to United Therapeutics
2.2 - Growth funds investing in similar companies to United Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for United Therapeutics
4.2 - Public trading comparable groups for United Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →